NASDAQ:TXMD

TherapeuticsMD Q4 2025 Earnings Results & Report

TherapeuticsMD logo
$1.71 -0.10 (-5.52%)
As of 11/20/2026 04:00 PM Eastern

TherapeuticsMD beat analyst earnings expectations but missed on revenue in its Q4 2025 results, released March 30, 2026. The company reported EPS of -$0.0530 versus the -$6.1250 consensus estimate, while revenue of $893 thousand fell short of the $19.77 million estimate by $18.88 million.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

TherapeuticsMD EPS Results

Actual EPS
-$0.0530
Consensus EPS
-$6.1250
Beat/Miss
Beat by +$6.0720
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

TherapeuticsMD Revenue Results

Actual Revenue
$893 thousand
Expected Revenue
$19.77 million
Beat/Miss
Missed by -$18.88 million
YoY Revenue Growth
N/A

TherapeuticsMD Q4 2025 Earnings FAQ

TherapeuticsMD (NASDAQ:TXMD) reported earnings of -$0.0530 per share for Q4 2025, beating the consensus estimate of -$6.1250. The report was announced on Monday, March 30, 2026.

TherapeuticsMD reported revenue of $893 thousand for Q4 2025, against a consensus estimate of $19.77 million.

TherapeuticsMD Earnings Headlines

Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) was a U.S. women’s health pharmaceutical company that developed and commercialized prescription products addressing contraception and symptoms associated with menopause. Its business was primarily focused on the U.S. market.

The company’s products included ANNOVERA, a reusable contraceptive vaginal system; IMVEXXY, estradiol vaginal inserts prescribed for certain menopausal symptoms; and BIJUVA, an oral estradiol and progesterone treatment for moderate-to-severe vasomotor symptoms associated with menopause in eligible women.

In 2023, TherapeuticsMD sold substantially all of its assets, including rights to these products, to Mayne Pharma. The products and commercial activities described here reflect TherapeuticsMD’s historical business.

View TherapeuticsMD Profile